Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Brain tumors brain mass )
8,667 results
  • Recurrent Glioblastomas Exhibit Higher Expression of Biomarkers with Stem-like Properties. [Journal Article]
  • JNJ Neurosci Rural Pract 2018 Jan-Mar; 9(1):86-91
  • Nandeesh BN, Naskar S, … Santosh V
  • CONCLUSIONS: A significant increase in the expression of SOX2 in recurrent tumors probably indicates the presence of undifferentiated cells with stem-like properties in these tumors. EGFR is known to mediate SOX2 expression thereby resulting in stemness of the glioma cancer cells, which could further explain its overexpression in recurrent GBMs. Furthermore, a decreased expression of TOP2A observed in the recurrent tumors could probably be due to reduction in chemosensitivity to temozolomide, which has been shown in earlier studies. We also noted that p53 expression remained unaltered in the recurrent tumors when compared to the primary, suggesting the absence of preferential clonal expansion of p53 mutant cells following exposure to radiochemotherapy. Our study reiterates the fact that GBM recurrences are associated with molecular alterations that probably contribute to radiochemoresistance, increased invasiveness, therapeutic efficacy, and stemness.
  • Skull metastasis revealing a renal tumor: A case report and review of the literature. [Journal Article]
  • IJInt J Surg Case Rep 2018 Feb 10; 43:56-60
  • Badri M, Gader G, … Zammel I
  • CONCLUSIONS: Although metastases to the head and neck occur infrequently, they should be considered when evaluating any unusual subcutaneous mass in the head and neck. RCC should not be discounted when sites as unlikely as the calvaria are evaluated. Treatment of metastatic renal cell carcinoma is complex, and the optimal regimen for achieving a lasting response without severe toxicity has not yet been defined.
  • Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature. [Case Reports]
  • MMedicine (Baltimore) 2017; 96(50):e9278
  • Song JC, Ding XL, … Tian J
  • CONCLUSIONS: In the case reported here, a delayed and mixed response was observed after Pembrolizumab was used. Because of causing severe pulmonary infection, the use of steroids should be considered carefully when treating immunorelated adverse events. It seemed that the Pembrolizumab has a positive effect on melanoma brain metastases especially combined with other treatments. However, there are still some challenges including patient selection, predictors of response, drug tolerance, optimizing combination strategies and control of adverse effects. More carefully designed clinical trials are urgently needed.
New Search Next